The Hemoglobin Glycation Index Identifies Subpopulations With Harms or Benefits From Intensive Treatment in the ACCORD Trial
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: This study tested the hypothesis that intensive treatment in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial disproportionately produced adverse outcomes in patients with diabetes with a high hemoglobin glycation index (HGI = observed HbA1c − predicted HbA1c). RESEARCH DESIGN AND METHODS: ACCORD was a randomized controlled trial of 10,251 patients with type 2 diabetes assigned to standard or intensive treatment with HbA1c goals of 7.0% to 7.9% (53 to 63 mmol/mol) and less than 6% (42 mmol/mol), respectively. In this ancillary study, a linear regression equation (HbA1c = 0.009 × fasting plasma glucose [FPG] [mg/dL] + 6.8) was derived from 1,000 randomly extracted participants at baseline. Baseline FPG values were used to calculate predicted HbA1c and HGI for the remaining 9,125 participants. Kaplan-Meier and Cox regression were used to assess the effects of intensive treatment on outcomes in patients with a low, moderate, or high HGI. RESULTS: Intensive treatment was associated with improved primary outcomes (composite of cardiovascular events) in the low (hazard ratio [HR] 0.75 [95% CI 0.59–0.95]) and moderate (HR 0.77 [95% CI 0.61–0.97]) HGI subgroups but not in the high HGI subgroup (HR 1.14 [95% CI 0.93–1.40]). Higher total mortality in intensively treated patients was confined to the high HGI subgroup (HR 1.41 [95% CI 1.10–1.80]). A high HGI was associated with a greater risk for hypoglycemia in the standard and intensive treatment groups. CONCLUSIONS: HGI calculated at baseline identified subpopulations in ACCORD with harms or benefits from intensive glycemic control. HbA1c is not a one-size-fits-all indicator of blood glucose control, and taking this into account when making management decisions could improve diabetes care.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Standards of medical care in diabetes 2010
American Diabetes Association (2010) · Diabetes Care · doi:10.2337/dc10-s011 · Cited by 3,470
Translating the A1C assay into estimated average glucose values
Nathan, D. M., Kuenen, J., Borg, R., Zheng, H., Schoenfeld, D., Heine, R. J., & for the A1c-Derived Average Glucose (ADAG) Study Group (2008) · Diabetes Care · doi:10.2337/dc08-0545 · Cited by 1,812
Long-term effects of intensive glucose lowering on cardiovascular outcomes
The ACCORD Study Group (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1006524 · Cited by 1,035
Bonds, D. E., Miller, M. E., Bergenstal, R. M., Buse, J. B., Byington, R. P., Cutler, J. A., Dudl, R. J., Ismail-Beigi, F., Kimel, A. R., Hoogwerf, B., et al. (2010) · BMJ · doi:10.1136/bmj.b4909 · Cited by 933 · cited 1×
“Although symptomatic severe hypoglycemia was associated with an increased risk of death in the intensive and standard treatment groups, differences in HbA1c or rates of hypoglycemia between the two groups did not explain the greater mortality observed in the intensive-treatment group (2).”
Self-citationAction to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: Design and Methods
Buse, J. B. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.03.003 · Cited by 661
Self-citationMiller, M. E., Bonds, D. E., Gerstein, H. C., Seaquist, E. R., Bergenstal, R. M., Calles-Escandon, J., Childress, R. D., Craven, T. E., Cuddihy, R. M., Dailey, G., et al. (2010) · BMJ · doi:10.1136/bmj.b5444 · Cited by 429 · cited 1×
“(3) paradoxically reported that ACCORD participants with higher HbA1c levels had greater risk for hypoglycemia.”
Riddle, M. C., Ambrosius, W. T., Brillon, D. J., Buse, J. B., Byington, R. P., Cohen, R. M., Goff, D. C., Malozowski, S., Margolis, K. L., Probstfield, J. L., et al. (2010) · Diabetes Care · doi:10.2337/dc09-1278 · Cited by 406
Self-citationCalles-Escandón, J., Lovato, L. C., Simons-Morton, D. G., Kendall, D. M., Pop-Busui, R., Cohen, R. M., Bonds, D. E., Fonseca, V. A., Ismail-Beigi, F., Banerji, M. A., et al. (2010) · Diabetes Care · doi:10.2337/dc09-1471 · Cited by 160 · cited 1×
“associated with intensive treatment in ACCORD (16,17).”
Self-citationPitfalls in the use of HbA1c as a diagnostic test: the ethnic conundrum
Dagogo-Jack, S. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.126 · Cited by 131
Cited by
The relationships between time in range, hyperglycemia metrics, and HbA1c
Beck, R. W., Bergenstal, R. M., Cheng, P., Kollman, C., Carlson, A. L., Johnson, M. L., & Rodbard, D. (2019) · Journal of Diabetes Science and Technology · doi:10.1177/1932296818822496 · Cited by 479
The fallacy of average: how using HbA1c alone to assess glycemic control can be misleading
Beck, R. W., Connor, C. G., Mullen, D. M., Wesley, D. M., & Bergenstal, R. M. (2017) · Diabetes Care · doi:10.2337/dc17-0636 · Cited by 477
Metrics for glycaemic control - from HbA1c to continuous glucose monitoring
Kovatchev, B. P. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.3 · Cited by 272
Nine-year effects of 3.7 years of intensive glycemic control on cardiovascular outcomes
The ACCORD Study Group (2016) · Diabetes Care · doi:10.2337/dc15-2283 · Cited by 193
“5% at baseline (20), or in the subgroup with the highest discrepancy between baseline HbA1c and the HbA1c levels that would be predicted from fasting plasma glucose levels (due to higher protein glycation, higher prandial glucose levels, or other reasons) (21).”
BackgroundPositioning time in range in diabetes management
Advani, A. (2020) · Diabetologia · doi:10.1007/s00125-019-05027-0 · Cited by 170
Metadata
- Authors
- Hempe, J. M., Liu, S., Myers, L., McCarter, R. J., Buse, J. B., & Fonseca, V.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2015-04-17
- Volume
- 38
- Issue
- 6
- Pages
- 1067-1074
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2099889406
- Cited by
- 233
- References
- 11
- FWCI
- 13.67
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Hemoglobin Glycation Index Identifies Subpopulations With Harms or Benefits From Intensive Treatment in the ACCORD Trial. https://app.cochat.ai/papers/10.2337/dc14-1844
- The paper
- Hempe, J. M., Liu, S., Myers, L., McCarter, R. J., Buse, J. B., & Fonseca, V. (2015). The Hemoglobin Glycation Index Identifies Subpopulations With Harms or Benefits From Intensive Treatment in the ACCORD Trial. Diabetes Care. https://doi.org/10.2337/dc14-1844
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.